Source comparison
BPC-157 Oral vs Injectable Route: Administration Comparison
| Administration Route | Bioavailability | Onset Time | Plasma Half-Life | Primary Use Case | Stability Requirement | Professional Assessment ||—|—|—|—|—|—|| Subcutaneous Injection | 90–95% | 15–30 min | ~4 hours (rodent data) | Systemic tissue repair, joint h
This comparison does not assign a generated winner or score.
- | Administration Route | Bioavailability | Onset Time | Plasma Half-Life | Primary Use Case | Stability Requirement | Professional Assessment ||—|—|—|—|—|—|| Subcutaneous Injection | 90–95% | 15–30 min | ~4 hours (rodent data) | Systemic tissue repair, joint healing, neuroprotection | Refrigerate reconstituted solution at 2–8°C; use within 28 days | Gold standard for systemic research. Bypasses gastric degradation entirely, achieves consistent plasma concentrations || Intramuscular Injection | 90–95% | 20–30 min | ~4 hours (rodent data) | Systemic endpoints requiring rapid absorption | Same as subcutaneous | Faster peak but same bioavailability. Choose based on injection site preference || Oral Administration | 0.1–5% | 60–90 min | <2 hours | Localised GI mucosal contact (ulcer models, IBD) | Same storage; administer on empty stomach for marginal improvement | Useful only for direct mucosal interaction research. Systemic activity unreliable due to degradation |